Signal from the log
Setara Biosciences
90 M$ · Series A · United States · Biotech
Setara Biosciences, à San Diego, reprend les programmes qu'Actio Biosciences a gardés après son rachat par Jazz Pharmaceuticals. Son médicament principal, STAR-0871, est une petite molécule orale qui bloque le canal TRPV4, en cause dans la maladie de Charcot-Marie-Tooth de type 2C ; il est aussi étudié contre l'hyperactivité vésicale.
Article
Announced on , logged by the watch of 30 October 2026.
- Operation
- Funding round
- Announced amount
- 90 M$
- Stage
- Series A
- Country
- United States
- Sector
- Biotech
What the log says
Editorial note, in French
Sujet traité. L'article donne les sources et la position de Bolus.
The investors
With Deerfield Management , Canaan , Droia Ventures , EcoR1 , Euclidean Capital , Regeneron Ventures
Provenance
Logged on 30 October 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Article The operation led to an article, with its sources checked one by one.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.